Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Exploring immunotherapy in colorectal cancer

Fig. 2

Mechanism of therapeutic resistance in ICB treatment. The reasons can be summarized as follows: insufficient tumor antigen presentation, tumor antigen presentation damage, T cell exclusion, and immunosuppressive signaling in the TME. The corresponding clinical trials are also marked in the figure

Back to article page